ArticleBioactive materials2024
Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment.
Article in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- Therapeutic potential ofPharmaceutical biology · 2026Review
- Organoid-loaded core-shell cryomicroneedles induce biomimetic follicular units and hair regeneration.Bioactive materials · 2026Article
- Microneedle-mediated intelligent combination delivery for hair regeneration: A comprehensive review of technologies, mechanistic evidence, and translational prospects.Materials today. Bio · 2026Review
- Versatile twin layer macromolecular fibers for advanced tissue engineering applications.iScience · 2026Article
- Nanoparticle-Hydrogel Composites for Precision Medicine.Cell biomaterials · 2026Article
- Microneedles self-implanting Astragalus polysaccharides-hybridized composite hydrogel combined with minoxidil to enhance in situ anti-androgenetic alopecia.Drug delivery and translational research · 2026Article
- A Disulfide-Sticker Strategy for Marine Adhesive Coatings: From Deciphering Self-Assembly Mechanism to Functional Application in Hair Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A dual-mechanism injectable hydrogel integrating reactive oxygen species regulationand low-level laser therapy for androgenetic alopecia remediation.Journal of nanobiotechnology · 2026Article
- Microneedle technology integrated with diverse therapeutic modalities for hair regrowth in alopecia.Acta pharmaceutica Sinica. B · 2026Review
- Dental pulp stem cell exosomes promote angiogenesis via the PI3K/Akt signaling pathway to treat androgenetic alopecia.Stem cell research & therapy · 2026Article
- Impeding glial scarring hyperplasia and activating axon neogenesis via immunomodulatory microneedle patch for spinal cord repair.Journal of nanobiotechnology · 2026Article
- Hydrogel microneedle delivery of a palmitoylated peptide promotes hair regeneration via dual activation of Wnt/β-catenin and cAMP-PKA signaling.Journal of nanobiotechnology · 2026Article
- Synergistic delivery of ginseng exosomes and biomimetic melanosomes via temporally controlled hydrogel microneedles restrain the pathologic triad of vitiligo.Journal of nanobiotechnology · 2026Article
- Synergy of dissolving microneedles and ultrasound to enhance transdermal delivery for rheumatoid arthritis.Drug delivery and translational research · 2026Article
- Fibroblast Growth Factor-7 and Hair Biology: Bridging Basic Science and Therapeutic Applications.Current issues in molecular biology · 2026Review
- Rational Design and Functionalization of Melt Electrowritten 4D Scaffolds for Biomedical Applications.Nano-micro letters · 2026Review
- Potential Cosmetic Applications of Dihydroartemisinin.Molecules (Basel, Switzerland) · 2026Article
- Particulate matter exposure induces maternal scalp hair loss after birth in C57/B6 mouse via alteration of inflammatory and apoptotic pathways.Frontiers in endocrinology · 2026Article
- Innovative microneedle-integrated hydrogels: a promising strategy for diabetic foot ulcer management.Frontiers in bioengineering and biotechnology · 2026Review
- Biomedical Technologies for Androgenic Alopecia Treatment: Advance, Mechanism and Future Direction.Research (Washington, D.C.) · 2026Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgenetic alopecia (AGA), the most prevalent clinical hair loss, lacks safe and effective treatments due to downregulated angiogenic genes and insufficient vascularization in the perifollicular microenvironment of the bald scalp in AGA patients. In this study, a hyaluronic acid (HA) based hydrogel-formed microneedle (MN) was designed, referred to as V-R-MNs, which was simultaneously loaded with vascular endothelial growth factor (VEGF) and the novel hair loss drug Ritlecitinib, the latter is encapsulated in slowly biodegradable polyhydroxyalkanoates (PHAs) nanoparticles (R-PHA NPs) for minimally invasive AGA treatment. The integration of HA based hydrogel alongside PHA nanoparticles significantly bolstered the mechanical characteristics of microneedles and enhanced skin penetration efficiency. Due to the biosafety, mechanical strength, and controlled degradation properties of HA hydrogel formed microneedles, V-R-MNs can effectively penetrate the skin's stratum corneum, facilitating the direct delivery of VEGF and Ritlecitinib in a minimally invasive, painless and long-term sustained release manner. V-R-MNs not only promoted angiogenesis and improve the immune microenvironment around the hair follicle to promote the proliferation and development of hair follicle cells, but also the application of MNs to the skin to produce certain mechanical stimulation could also promote angiogenesis. In comparison to the clinical drug minoxidil for AGA treatment, the hair regeneration effect of V-R-MN in AGA model mice is characterized by a rapid onset of the anagen phase, improved hair quality, and greater coverage. This introduces a new, clinically safer, and more efficient strategy for AGA treatment, and serving as a reference for the treatment of other related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.